GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Quick Ratio

Revelation Biosciences (FRA:56U0) Quick Ratio : 2.18 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Revelation Biosciences's quick ratio for the quarter that ended in Dec. 2023 was 2.18.

Revelation Biosciences has a quick ratio of 2.18. It generally indicates good short-term financial strength.

The historical rank and industry rank for Revelation Biosciences's Quick Ratio or its related term are showing as below:

FRA:56U0' s Quick Ratio Range Over the Past 10 Years
Min: 0.89   Med: 1.7   Max: 3.82
Current: 2.18

During the past 4 years, Revelation Biosciences's highest Quick Ratio was 3.82. The lowest was 0.89. And the median was 1.70.

FRA:56U0's Quick Ratio is ranked worse than
62.97% of 1553 companies
in the Biotechnology industry
Industry Median: 3.49 vs FRA:56U0: 2.18

Revelation Biosciences Quick Ratio Historical Data

The historical data trend for Revelation Biosciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Quick Ratio Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Quick Ratio
3.82 0.89 1.22 2.18

Revelation Biosciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.22 2.23 3.45 2.62 2.18

Competitive Comparison of Revelation Biosciences's Quick Ratio

For the Biotechnology subindustry, Revelation Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revelation Biosciences's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's Quick Ratio falls into.



Revelation Biosciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Revelation Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(11.14-0)/5.103
=2.18

Revelation Biosciences's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(11.14-0)/5.103
=2.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revelation Biosciences  (FRA:56U0) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Revelation Biosciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Revelation Biosciences (FRA:56U0) Business Description

Traded in Other Exchanges
Address
4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines